Amgen Beats Earnings Estimates as Revenue Growth Hits 9.5%

Pharmaceutical giant Amgen reported its Q2 financials on October 2, with revenue growth of 9.5% to $10.05 billion.

The company's earnings per share (EPS) beat analyst estimates at $6.29 against a consensus estimate of $5.62.

Amgen attributed this success to its diverse pipeline, including the ongoing Phase 3 studies for dazodalibep in treating systemic Sjogren's disease.

The company maintained its fiscal year 2026 EPS guidance of $22.30-$23.50 and expects the completion of another key study in Q4 2026.